Welcome to BRIDGE PHARMA, Inc.

BRIDGE PHARMA, Inc. is a privately held research and development company focusing exclusively on pharmaceutical projects with blockbuster potential. These projects address unmet medical needs within large and growing global markets. BRIDGE PHARMA's projects offer new therapies with significant improvements and advantages over existing treatments.
The Company has several research projects with blockbuster potential, and its highly experienced project team members have numerous successfully marketed drugs to their credit.

Corporate Profile

BRIDGE PHARMA's current human projects include the development of new drugs for atopic dermatitis, asthma, pruritus, allergic conjunctivitis, and dry eye disease (xerophthalmia).

BRIDGE PHARMA's veterinary projects include drugs for treatment of canine atopic dermatitis, canine xerophthalmia, as well as repartitioning agents (growth promoters) for livestock.

Main offices of BRIDGE PHARMA are located in Sarasota FL, USA. Most of the Company's chemistry research is performed in collaboration with GLSynthesis, Inc. in Worcester, MA. Biological laboratory research is performed in collaboration with selected CROs and other specialists in the US, Canada, Europe and New Zealand.

BRIDGE PHARMA, Inc. develops and tests its drugs through the preclinical phases, whereupon the Company seeks out-licensing partners. The Company has out-licensed drugs in such diverse market segments as local anesthetics, urinary urge incontinence, ocular projects, and livestock growth promotion

We are currently updating our web site. Please check back later for updates.